Search Results
Precision Medicine For DNMT3A-Mutant T-cell ALL
T-cell ALL is an aggressive blood cancer with poor overall survival, high relapse rates, and significant treatment-related side effects. Using primary T-ALL patient samples, this project will study the importance of JAK/STAT signaling and the gene BIRC5 in the pathology of T-ALL driven by DNMT3A mutations using genetic and pharmacological tools. The goal of this proposal is to develop precision medicine approaches for DNMT3A-mutant adult T-ALL patients, a group with poor clinical outcomesTargeting HSP70 to Immune Effector Cells to Overcome the Immune Suppressive Myeloma Microenvironment
Development of a strong anti-cancer immune response requires coordinated action of the innate and adaptive parts of the immune system, but cancer cells alter their environment to suppress virtually every step in this process, which promotes cancer progression and treatment resistance. One promising strategy could be to target Heat shock protein 70 (HSP70), which plays an important role in both innate and adaptive immunity, and we therefore developed a series of novel antibodies to HSP70, one of which cured mice of multiple myeloma.Impact of sublethal radiation dose on tumor response, microenvironment and the immune system
Extremely low dose radiation can improve blood cancer outcomes. But the mechanisms of how sublethal radiation (SRT) affects tumors, the microenvironment and immune system remain unclear. We envision a broad, nuanced role for SRT with benefits across diverse clinical situations and propose 3 clinical trials with deep translational components. Each can be paradigm-changing, but are thematically unified to improve mechanistic understanding of how such exceptionally small doses might offer so much.Blastic plasmacytoid dendritic cell neoplasm (BPDCN): understanding disease biology to improve therapy
We focus on blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive blood cancer with limited treatment options and poor outcomes. We want to understand what causes the disease, develop laboratory tools, and identify new treatments and ways to overcome therapy resistance. We have translated our discoveries to clinical trials. Our goal is to continue this bench to beside approach to develop the next generation of BPDCN therapies that improve survival and minimize treatment toxicity.Role of Health Insurance and Medicaid Expansion in Racial Inequity in Patterns of Care and Outcomes in Multiple Myeloma
Multiple myeloma is the most common blood cancer in African Americans. Thanks to advances in treatment, over 50% of patients now survive 5 years compared to 35% in 2000. However, African American patients may not be enjoying the same health gain as White patients, possibly due to poorer access to healthcare. This study will examine the role of health insurance and living in states with expanded eligibility for Medicaid on treatment patterns and survival in African Americans compared to White patients with multiple myeloma.Pan-heme CAR: Anti-CD38 CAR T cells for myeloid, lymphoid and plasma cell malignancies
Our SCOR team has a razor-sharp focus on an exciting new treatment modality for blood cancers: chimeric antigen receptor (CAR) T cells. T cells can be trained to target cancer cells by genetic modification. In fact, previous support from the Leukemia & Lymphoma Society allowed us to successfully develop CAR T cells targeted to CD19, a pan-B cell marker.Exploiting tumor-immune dynamics to inform curative combination therapy for follicular lymphoma
Follicular lymphoma is a common form of blood cancer, affecting 15,000 new patients annually in the United States, but it remains incurable with conventional treatments. Bispecific antibodies represent a new class of therapies that engage the immune system to attack lymphoma cells and have shown promising effectiveness in inducing remissions in patients with this disease, but even they are unlikely to be curative.
Peer-to-Peer Support
Patti Robinson Kaufmann First Connection® ProgramIf you or a family member has been diagnosed with a blood cancer, you may find it helpful to speak with someone who has gone through a similar experience and learned how to manage the same disease you're trying to cope with each day. The Patti Robinson Kaufmann First Connection® Program is a free service of The Leukemia & Lymphoma Society (LLS) that introduces patients and their loved ones to a trained peer volunteer who has gone through a similar experience.
Development of BET protein bromodomain inhibitors for the treatment of patients with hematologic malignancies
In July 2012, LLS began its partnership with Constellation to support three first-in-human Phase 1 clinical trials for blood cancer patients and the partnership led to the ongoing trial "A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients."Targeting the inflammatory GM-CSF pathway in high risk CMML
Chronic myelomonocytic leukemia (CMML) is a rare but poorly understood blood cancer often presenting with crippling inflammatory symptoms that frequently evolves into acute leukemia. In an ongoing clinical trial, we have compelling molecular and clinical data that this disease responds effectively to blockade of GM-CSF with lenzulimab, a well-tolerated and safe antibody, in combination with azacitidine.A phase 2 expansion study of ICT01, an anti-BTN3A monoclonal antibody, in combination with azacitidine and venetoclax in patients with AML
In June 2022, LLS made an equity investment in ImCheck Therapeutics to "Support Clinical Development of the ICT01 Program for Blood Cancer Indications." ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators.REACH: Recruitment Expansion through community Access to Clinical trials in Hematologic malignancies
Mayo Clinic Rochester (MCR) is a tertiary center with 35,000 blood cancer visits annually. Circa 70% of patients referred to MCR come from 5 states: MN, WI, IA, SD and ND inhabited by 10,483,946 people living primarily in a rural setting. To improve local care access, MCR has developed the Mayo Clinic Health System (MCHS), a network of 17 community sites of which 7 have oncology care. In 2018, the MCR joined with the University of Minnesota to establish the Minnesota Cancer Clinical Trials Network (MCCTN) that includes 18 sites.LLS Research Spotlight
This is your connection to the latest in LLS Research. LLS-funded researchers are making strides toward new therapies and pathways to cures for blood cancers. We're highlighting some of these researchers with detailed summaries of their latest publications and success stories, designed to give you an idea of the latest happenings in blood cancer research.
Pluripotent Stem Cell-derived CAR-T and CAR-NK Cells for Immunotherapy of Leukemia and Lymphoma
Cytotoxic cells of the immune system, including T and NK cells, can be targeted to seek out and destroy leukemia, lymphoma and myeloma cells by engineering them to express chimeric antigen receptors (CARs) which empower the cell to home to and kill the cancer cells. Typically, such CAR-T and CAR-NK cells are generated from a patient's own blood, but sometimes heavy pre-treatment with chemotherapy leaves inadequate supplies of T and NK cells.Epigenetic Mechanisms and Targeting in Hematological Malignancy
Blood cancers can be caused by aberrant regulation of genes that control cell growth and development. The root cause of this problem may be the presence of mutant regulator proteins in the cell and abnormal switching on or off of target genes. Our SCOR studies the molecular basis of this gene deregulation using cell cultured in the laboratory, in human specimen and animal models.A phase 1 study of CB-012, a CRISPR-edited allogeneic CAR-T targeting CLL1, in patients with acute myeloid leukemia
In February 2021, LLS made an equity investment in Caribou Biosciences to "Support allogeneic CD371 (CLL-1) CAR development for acute myeloid leukemia." Caribou is a clinical-stage biotechnology company, co-founded by CRISPR pioneer and Nobel Prize winner Jennifer Doudna, Ph.D., using next-generation CRISPR genome-editing technology to develop “off-the-shelf” (allogeneic) CAR therapies for hard-to-treat blood cancers.Enhancing the “fitness” of anti-BCMA CAR T cells for improved efficacy in multiple myeloma
Chimeric antigen receptor (CAR) T cell therapy is a form of immune-based therapy where a patient’s own immune cells are genetically engineered to recognize and kill the tumor cells. This therapy has revolutionized the treatment of certain blood cancers and excitingly, two CAR T cell products were recently approved for the treatment of multiple myeloma.Subaru Loves to Care
The Leukemia & Lymphoma Society (LLS) is partnering with Subaru and its retailers to spread hope, love, and warmth to blood cancer patients and their families for the sixth consecutive year. As part of Subaru Loves to Care, we’re providing information on free education and support services from LLS to those fighting blood cancers across the country.
Who We Are
The Leukemia & Lymphoma Society is at the forefront of the fight to cure cancer. We are the largest nonprofit dedicated to creating a world without blood cancers. Since 1949, we’ve invested nearly $1.3 billion in groundbreaking research, pioneering many of today’s most innovative approaches.
Cancer is a heck of an opponent.
It's a bully. But we aren't afraid of a fight. It's elusive. But our focus never fades. It's deadly. But we are known, cancer killers.
Caregiver Support
Am I A Caregiver?If you’re providing regular assistance, you are a caregiver. Your loved one may only need support occasionally, or your loved one may need constant care. The kind of support needed will be different for each person and may also change over time. But if you're consistently providing care, you are a caregiver.
Here are just a few examples of caregiver tasks:
Myeloma
Is a type of cancer that begins in the bone marrow. It is a cancer of plasma cells, which are a type of white blood cells (also called plasma B cells). The disease belongs to a spectrum of disorders referred to as “plasma cell dyscrasias” or "plasma cell neoplasms", and has several forms.
Lymphoma
Lymphoma is the name for a group of blood cancers that develop in the lymphatic system. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL).
Treatment
Which side effects do I need to call my doctor about? Side effects of treatment are usually discussed with patients before the treatment is started. From the doctor's perspective, the side effects of greatest concern may be fever, breathing difficulties, hives or rashes, rapid heartbeat, confusion, and redness or pain at the IV site. From the patient's perspective, any side effect causing discomfort or limiting usual activity, such as diarrhea or nausea, is a concern. Report any side effects when they first appear.
Coloring App
The free coloring app allows children to express their creativity and also offers activities to help them learn about blood cancer and its treatment.